Charles Schwab Investment Management Inc Black Diamond Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $521 Billion
- Q1 2025
A detailed history of Charles Schwab Investment Management Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 109,224 shares of BDTX stock, worth $237,016. This represents 0.0% of its overall portfolio holdings.
Number of Shares
109,224
Previous 109,224
-0.0%
Holding current value
$237,016
Previous $233,000
27.47%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding BDTX
# of Institutions
94Shares Held
41.1MCall Options Held
45.1KPut Options Held
37K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.4MShares$22.6 Million0.01% of portfolio
-
Vestal Point Capital, LP New York, NY5.6MShares$12.2 Million0.62% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$9.65 Million0.65% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$6.98 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V82.73MShares$5.93 Million0.1% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $78.9M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...